Insulet
(Nasdaq: PODD)
announced today that it received CE mark approval for the integration of the Abbott
(NYSE: ABT)
FreeStyle Libre 2 Plus with Omnipod 5.
European approval covers the compatibility of Abbott’s glucose sensor with the Insulet automated insulin delivery system for individuals aged two years and older with type 1 diabetes.
Currently, Omnipod 5 works with Dexcom CGM. Right now, it has compatibility with the previous-generation G6 as the companies work on integrating the G7. However, Insulet hinted at the future integration with Abbott’s popular FreeStyle Libre system midway through last year.
This also marks the second major insulin pump integration for Abbott in 2024. Last month, the company announced FreeStyle Libre 2 Plus compatibility with the Tandem Diabetes Care t:slim X2 system.
Get the full story at our sister site, Drug Delivery Business News.